FY2025 Earnings Forecast for LXEO Issued By Leerink Partnrs

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Investment analysts at Leerink Partnrs dropped their FY2025 earnings estimates for shares of Lexeo Therapeutics in a report released on Monday, March 24th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($3.18) per share for the year, down from their prior forecast of ($3.00). The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ FY2026 earnings at ($2.67) EPS and FY2027 earnings at ($2.63) EPS.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its earnings results on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.09.

Other equities analysts also recently issued research reports about the company. Royal Bank of Canada decreased their target price on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday. Leerink Partners dropped their target price on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research report on Monday. HC Wainwright reiterated a “buy” rating and set a $23.00 price target on shares of Lexeo Therapeutics in a research report on Wednesday. Finally, Chardan Capital restated a “buy” rating and issued a $25.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Lexeo Therapeutics has an average rating of “Buy” and an average target price of $22.80.

Lexeo Therapeutics Trading Up 3.0 %

LXEO opened at $4.11 on Thursday. Lexeo Therapeutics has a one year low of $2.32 and a one year high of $19.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. The business has a 50 day simple moving average of $4.07 and a two-hundred day simple moving average of $6.63. The firm has a market capitalization of $135.90 million, a price-to-earnings ratio of -1.30 and a beta of 3.85.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Wellington Management Group LLP grew its stake in shares of Lexeo Therapeutics by 48.3% in the 4th quarter. Wellington Management Group LLP now owns 76,981 shares of the company’s stock worth $507,000 after buying an additional 25,089 shares during the last quarter. Woodline Partners LP boosted its stake in Lexeo Therapeutics by 0.8% in the 4th quarter. Woodline Partners LP now owns 858,691 shares of the company’s stock worth $5,650,000 after purchasing an additional 6,730 shares in the last quarter. Vestal Point Capital LP boosted its stake in Lexeo Therapeutics by 41.2% in the 4th quarter. Vestal Point Capital LP now owns 1,200,000 shares of the company’s stock worth $7,896,000 after purchasing an additional 350,000 shares in the last quarter. Point72 Asset Management L.P. grew its position in Lexeo Therapeutics by 102.5% during the 4th quarter. Point72 Asset Management L.P. now owns 750,235 shares of the company’s stock valued at $4,937,000 after purchasing an additional 379,828 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in Lexeo Therapeutics by 282.5% in the fourth quarter. Millennium Management LLC now owns 141,951 shares of the company’s stock worth $934,000 after buying an additional 104,837 shares during the last quarter. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.